Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25801239 | 0.84 | PDCD1 (0.36) | ABL1LRRK2PDE10APRCPMAPK1 | |
| SCHEMBL24150990 | 0.83 | ABL1 (0.33) | ACACBABL1LRRK2PDE10APRCP | |
| SCHEMBL24151086 | 0.72 | PDCD1 (0.36) | ABL1LRRK2PRCPMAPK1ATR | |
| SCHEMBL30218978 | 0.71 | PDCD1 (0.35) | ABL1LRRK2PDE10APRCPMAPK1 | |
| SCHEMBL24151044 | 0.71 | PDCD1 (0.35) | ABL1LRRK2PDE10APRCPMAPK1 | |
| SCHEMBL30218987 | 0.70 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL24151110 | 0.69 | PDCD1 (0.34) | ABL1LRRK2PRCPATRATRIP | |
| SCHEMBL25801322 | 0.67 | KDM4E (0.30) | — | |
| SCHEMBL21062752 | 0.65 | PDE10A (0.37) | PDE10A | |
| SCHEMBL12179244 | 0.65 | PDE10A (0.34) | ACACBPDE10AAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | PTPN5, PTPN1, PTPN2 | ACACB 3271/4885ABL1 59/4885LRRK2 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.